1. A combined preparation lercanidipine and losartan, characterized in that the content of lercanidipine hydrochloride is 0.5-40 wt.%, And losartan potassium content is 6.25-50 wt.%, By weight of the combined preparata.2. Combined preparation according to claim 1, characterized in that the weight ratio of lercanidipine hydrochloride to losartan potassium as active ingredients in the pharmaceutical combination formulation optimally is 1:. 2-25.3. Combined preparation according to claim. 1, characterized in that the applied auxiliaries are lactose monohydrate, 20-40%, 10-40% microcrystalline cellulose 10-20% Sodium starch glycolate type A, 8.2% povidone K30, 0.5 2.5% magnesium stearate, 5-15% pregelatinized starch and 1-10% colloidal silica kremniya.4. Combined preparation according to claim. 3, characterized in that it comprises a coating of Opadry white (opadry white) .5. A process for preparing a combined preparation according to claim 4, characterized in that it comprises the following steps: Step 1: sieved active pharmaceutical ingredients:. Lercanidipine hydrochloride and losartan - mixed and homogenized with lactose monohydrate, microcrystalline cellulose, starch glycolate sodium type A, povidone K30 magnesium stearate, pregelatinized starch and colloidal silicon dioxide followed by vacuum pressing and milling, sieved, granulated and tableted in the regulation firmly ti tablet core Step 2: Opadry was added to ethanol with stirring to obtain a dispersion, then added to purified water and stirred to obtain a solution of the insulating coating, which is then used for applying a film of1. Комбинированный препарат лерканидипина и лозартана, характеризующийся тем, что содержание в нем лерканидипина гидрохлорида составляет 0,5-40 мас.%, а содержание лозартана калия составляет 6,25-50 мас.%, от массы комбинированного препарата.2. Комбинированный препарат по п. 1, характеризующийся тем, что массовое отношение лерканидипина гидрохлорида к лозартану калия в качестве актив
